{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:02:33Z","timestamp":1785420153006,"version":"3.56.0"},"reference-count":49,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi"},{"id":[{"id":"https:\/\/ror.org\/00pgqb537","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The literature on the qualitative experiences of patients with non-Hodgkin lymphoma (NHL) is limited. Qualitative interviews were conducted to investigate participants\u2019 experiences with two types of NHL (diffuse large B-cell lymphoma [n = 20] and mantle cell lymphoma [n = 10]) and evaluate the comprehensiveness of patient-reported outcome (PRO) measures. Fatigue, tiredness, body aches, night sweats, lethargy, headache, appetite loss, altered taste, and weakness were the most frequent and bothersome symptoms. Key impacts were decreased physical performance, restricted activity, sadness, distress, fear of recurrence, and worry about future. Most participants expressed positive opinions about the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire\u2013Core 30 (EORTC QLQ-C30) (n = 22\/28), EORTC QLQ-NHL-High Grade Module 29 (EORTC QLQ-NHL-HG29) (n = 12\/16), EORTC QLQ-NHL-Low Grade Module 20 (EORTC QLQ-NHL-LG20) (n = 8\/12), and Functional Assessment of Cancer Therapy\u2013Lymphoma (FACT-Lym) (n = 10\/14), considering them relevant to their experiences (22\/27, 13\/15, 9\/13, and 10\/12, respectively). All measures adequately captured their experiences with NHL (QLQ-C30: n = 26\/26, NHL-HG29: n = 14\/14, NHL-LG20: n = 11\/11, and FACT-Lym: n = 12\/13). These findings provide a valuable framework for informing the selection of appropriate PRO measures in NHL clinical trials and identifying potentially meaningful trial endpoints.<\/jats:p>","DOI":"10.3390\/curroncol33070427","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:09:09Z","timestamp":1784527749000},"page":"427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints"],"prefix":"10.3390","volume":"33","author":[{"given":"Amy","family":"Clark","sequence":"first","affiliation":[{"name":"PPD\u2122 Evidera\u2122 Patient-Centered Research, Thermo Fisher Scientific, London W6 8BJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4737-0987","authenticated-orcid":false,"given":"Sophie Van","family":"Tomme","sequence":"additional","affiliation":[{"name":"Sanofi, 1105 BP Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Hetherington","sequence":"additional","affiliation":[{"name":"PPD\u2122 Evidera\u2122 Patient-Centered Research, Thermo Fisher Scientific, London W6 8BJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Dias","family":"Barbosa","sequence":"additional","affiliation":[{"name":"PPD\u2122 Evidera\u2122 Patient-Centered Research, Thermo Fisher Scientific, London W6 8BJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cordero","sequence":"additional","affiliation":[{"name":"Sanofi, Reading RG6 1PT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Habermann","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5948170","DOI":"10.1155\/2024\/5948170","article-title":"Advancements in B-Cell Non-Hodgkin\u2019s Lymphoma: From Signaling Pathways to Targeted Therapies","volume":"2024","author":"Alfaifi","year":"2024","journal-title":"Adv. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.4143\/crt.2017.207","article-title":"Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study","volume":"50","author":"Kang","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_6","first-page":"266","article-title":"Understanding the factors influencing quality of life among survivors of Non-Hodgkin lymphoma after completing primary treatment: A systematic review","volume":"34","author":"Lekdamrongkul","year":"2026","journal-title":"Support. Care Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wasse, S.K., Assogba, E., Orazio, S., Atsou, K.M., Rossi, C., Guilloteau, A., Gauthier, S., Girard, S., Poncet, J.M., and Damaj, G. (2025). Health-Related Quality of Life in Long-Term Survivors of Non-Hodgkin Lymphoma: A French Population-Based Study. Cancers, 17.","DOI":"10.3390\/cancers17040711"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pai, R.R., Ghoshal, A., Udupa, K., Pai, A., Mailankody, S., Damani, A., Rao, K.S., Prabhu, S., Nayak, M.G., and Salins, N. (2025). Assessing palliative care needs in adult patients with hematological malignancies and their caregivers: Implications for referral practice. BMC Palliat. Care, 24.","DOI":"10.1186\/s12904-025-01811-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4103\/apjon.apjon_41_20","article-title":"Unmet Supportive Care Needs of Patients with Hematological Malignancies: A Systematic Review","volume":"8","author":"Tsatsou","year":"2021","journal-title":"Asia Pac. J. Oncol. Nurs."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-18-0037","article-title":"Harnessing the Power of Patient-Reported Outcomes in Oncology","volume":"24","author":"Nipp","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.2015.63.6480","article-title":"Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010\u20132014)","volume":"34","author":"Gnanasakthy","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_13","unstructured":"Food and Drug Administration (2018). Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stake Holders, Final Guidance."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.mayocp.2019.04.005","article-title":"Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology","volume":"94","author":"Warsame","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","article-title":"International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia","volume":"27","author":"Oerlemans","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","article-title":"A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","unstructured":"Zumbo, B.D., and Hubley, A.M. (2017). Cognitive interviewing and think aloud methods. Understanding and Investigating Response Processes in Validation Research, Springer International Publishing\/Springer Nature."},{"key":"ref_19","unstructured":"Food and Drug Administration (2022). Patient-Focused Drug Development: Methods to Identify What Is Important to Patients."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/10428194.2023.2210711","article-title":"The experience of patients with acute myeloid leukemia in remission post-transplant","volume":"64","author":"Cella","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11764-022-01279-9","article-title":"Development of a disease conceptual model of patient experience with metastatic colorectal cancer: Identification of the most salient symptoms and impacts","volume":"18","author":"Guillemin","year":"2024","journal-title":"J. Cancer Surviv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11136-021-02903-4","article-title":"Understanding the patient experience in hepatocellular carcinoma: A qualitative patient interview study","volume":"31","author":"Patel","year":"2022","journal-title":"Qual. Life Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1038\/bcj.2015.29","article-title":"Haematological cancer and quality of life: A systematic literature review","volume":"5","author":"Porro","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_24","first-page":"1110","article-title":"Exploring the link between unmet needs and quality of life in lymphoma survivors: A cross-sectional study","volume":"33","author":"Boland","year":"2025","journal-title":"Support. Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.7314\/APJCP.2014.15.17.7153","article-title":"Symptoms and symptom clusters in non Hodgkin\u2019s lymphoma patients in Turkey","volume":"15","author":"Bolukbas","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jin, J., Ren, S., Zhang, W., Yang, P., Yang, J., Xu, H., Han, B., Zhang, W., and Liu, J. (2025). Patient-reported symptom burden and health-related quality of life in patients with aggressive Non-Hodgkin lymphoma: A cross-sectional study. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14730-8"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejon.2018.07.003","article-title":"The lived experience of patients with non-Hodgkin\u2019s lymphoma undergoing chemotherapy","volume":"35","author":"Chircop","year":"2018","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s11136-021-03003-z","article-title":"Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: A systematic review of qualitative studies","volume":"31","author":"Campbell","year":"2022","journal-title":"Qual. Life Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1182\/blood.V120.21.4703.4703","article-title":"Difficulties with Measuring the Patient\u2019s Perspective in Non Hodgkin\u2019s Lymphoma\u2014A Review of Patient Reported Outcome Measures","volume":"120","author":"Mehta","year":"2012","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"147176","DOI":"10.1155\/2013\/147176","article-title":"The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin\u2019s Lymphoma: The Functional Assessment of Cancer Therapy\u2014Lymphoma (FACT-Lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"ref_33","unstructured":"National Cancer Institute (2025). SEER Cancer Stat Facts: Non-Hodgkin Lymphoma, Surveillance, Epidemiology, and End Results Program."},{"key":"ref_34","unstructured":"National Guideline Alliance (UK) (2016). Non-Hodgkin\u2019s Lymphoma: Diagnosis and Management, Guideline, No 52."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2012.064907","article-title":"A high level of fatigue among long-term survivors of non-Hodgkin\u2019s lymphoma: Results from the longitudinal population-based PROFILES registry in the south of the Netherlands","volume":"98","author":"Oerlemans","year":"2013","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e037460","DOI":"10.1136\/bmjopen-2020-037460","article-title":"Exercise barriers and facilitators during hematopoietic stem cell transplantation: A qualitative study","volume":"10","author":"Yu","year":"2020","journal-title":"BMJ Open"},{"key":"ref_37","first-page":"807","article-title":"Qualitative analysis of prior knowledge, concerns, and expectations of patients with relapsed\/ refractory large B-cell lymphoma enrolled in 2 trials of lisocabtagene maraleucel (liso-cel","volume":"4","author":"Hasskarl","year":"2024","journal-title":"HemaSphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.3399\/bjgp19X701009","article-title":"Disease-related factors affecting timely lymphoma diagnosis: A qualitative study exploring patient experiences","volume":"69","author":"Howell","year":"2019","journal-title":"Br. J. Gen. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1177\/1359105316660179","article-title":"\u2018Haematological cancers, they\u2019re a funny bunch\u2019: A qualitative study of non-Hodgkin\u2019s lymphoma patient experiences of unmet supportive care needs","volume":"23","author":"Swash","year":"2018","journal-title":"J. Health Psychol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/jan.13790","article-title":"The use of metaphors in non-Hodgkin\u2019s lymphoma patients undergoing chemotherapy","volume":"74","author":"Chircop","year":"2018","journal-title":"J. Adv. Nurs."},{"key":"ref_41","first-page":"2429","article-title":"Coping with non-Hodgkin\u2019s lymphoma: A qualitative study of patient perceptions and supportive care needs whilst undergoing chemotherapy","volume":"25","author":"Chircop","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_42","first-page":"4082","article-title":"Patient and physician preferences for front-line treatment of advanced stage hodgkin lymphoma in germany, france and the united kingdom","volume":"130","author":"Broeckelmann","year":"2017","journal-title":"Blood"},{"key":"ref_43","first-page":"2445","article-title":"Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma","volume":"25","author":"Lie","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1188\/16.ONF.E195-E2014","article-title":"The Experiences of Young Adults with Hodgkin Lymphoma Transitioning to Survivorship: A Grounded Theory Study","volume":"43","author":"Matheson","year":"2016","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/j.1365-2648.2011.05657.x","article-title":"Experiences prior to diagnosis of non-Hodgkin lymphoma: A phenomenological study","volume":"67","author":"Wall","year":"2011","journal-title":"J. Adv. Nurs."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3109\/0284186X.2010.550934","article-title":"Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects","volume":"50","author":"Hess","year":"2011","journal-title":"Acta Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/nur.20143","article-title":"Three months in the symptom life of a teenage girl undergoing treatment for cancer","volume":"29","author":"Docherty","year":"2006","journal-title":"Res. Nurs. Health"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1188\/05.ONF.1131-1141","article-title":"Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach","volume":"32","author":"Crom","year":"2005","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejon.2004.08.002","article-title":"The lived experience post-autologous haematopoietic stem cell transplant (HSCT): A phenomenological study","volume":"9","author":"Stephens","year":"2005","journal-title":"Eur. J. Oncol. Nurs."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:27:29Z","timestamp":1784608049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070427"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070427","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}